Potential Myastenia Gravis Therapy, PRTX-100, Again Seen to Reduce Disease Activity in Mouse Model
Protalex’s lead treatment candidate PRTX-100 again showed the potential to lessen disease activity and preserve grip strength in a second study in a mouse model of myasthenia gravis (MG). These findings, from an interim analysis of a study led by researchers at George Washington University, are intended to to…